Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global Transthyretin Amyloidosis (ATTR) market size was valued at USD 3.2 billion in 2024 and is projected to reach USD 6.8 billion by 2031, exhibiting a CAGR of 11.3% during the forecast period, according to recent market analysis.
Transthyretin Amyloidosis (ATTR) is a rare, progressive disease caused by abnormal accumulation of misfolded transthyretin protein in tissues, leading to organ dysfunction. This condition manifests in two primary forms: hereditary ATTR (hATTR) resulting from genetic mutations, and wild-type ATTR (wtATTR) which occurs spontaneously without genetic predisposition. The disease predominantly affects the nervous system and heart, with wtATTR accounting for approximately 60% of cardiac amyloidosis cases in patients over 60 years old.
The market growth is driven by several key factors, including increasing disease awareness, improved diagnostic capabilities, and the launch of novel therapeutics like RNA interference drugs and stabilizers. North America currently dominates the market, accounting for over 45% of global revenue in 2024, due to higher diagnosis rates and accelerated drug approvals. Recent developments, such as the FDA approval of new gene-silencing therapies from Alnylam Pharmaceuticals in 2022, have significantly expanded treatment options and contributed to market expansion. Leading players including Pfizer, Ionis Pharmaceuticals, and Alnylam Pharmaceuticals continue to invest heavily in clinical trials to address unmet needs in both hATTR and wtATTR patient populations.
Increasing Prevalence of ATTR Amyloidosis
The global ATTR amyloidosis market is being driven by the rising prevalence of both hereditary and wild-type forms of the disease. Recent studies indicate that wild-type ATTR amyloidosis affects approximately 10-15% of adults over age 80, while hereditary variants are being diagnosed with increasing frequency due to improved genetic testing.
Advancements in Diagnostic Technologies
The development of non-invasive diagnostic tools such as technetium pyrophosphate scintigraphy and advanced cardiac MRI techniques has significantly improved early detection rates. These technologies have reduced diagnostic delays from an average of 4-5 years to under 2 years in many cases.
The global ATTR amyloidosis therapeutics market is projected to grow at a CAGR of 11.3% from 2023 to 2030, driven by both increased diagnosis and treatment adoption.
Lastly, expanded approvals of disease-modifying therapies like tafamidis and patisiran across major markets have created a robust treatment landscape, further accelerating market growth.
MARKET CHALLENGES
High Treatment Costs and Limited Access
Despite therapeutic advances, prohibitive pricing remains a significant barrier, with annual treatment costs for ATTR therapies often exceeding $200,000. This creates substantial challenges for market penetration, particularly in developing regions and for payers managing budget constraints.
Other Challenges
Diagnostic Delays
Many patients still experience prolonged diagnostic journeys due to the non-specific nature of early symptoms and lack of awareness among primary care physicians about this rare condition.
Regulatory and Reimbursement Hurdles
Stringent regulatory requirements for rare disease therapies and complex reimbursement pathways continue to restrain market growth. Many health systems require extensive real-world evidence before providing full coverage for newer ATTR treatments, creating adoption delays.
Emerging Therapeutic Approaches
The pipeline contains several innovative mechanisms including CRISPR-based therapies, small molecule stabilizers, and novel RNA interference drugs that could transform treatment paradigms. Current clinical trials show particular promise for combination therapies targeting different aspects of the amyloidogenic process.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Hereditary ATTR represents the dominant segment due to its genetic nature and well-defined clinical profile including distinct subtypes. The hATTR segment demonstrates higher treatment urgency compared to wild-type, driving more immediate therapeutic interventions. Research focus remains particularly strong on polyneuropathy and cardiomyopathy variants within hereditary forms. |
| By Application |
|
Hospitals maintain leadership as the primary treatment centers for ATTR amyloidosis due to the complex diagnostic requirements and multidisciplinary care needs. The segment benefits from established referral networks for rare diseases and existing infrastructure for comprehensive patient management. Specialty clinics are emerging as important secondary care venues with increasing disease awareness. |
| By End User |
|
Geriatric Patients constitute the predominant end-user group, particularly for wild-type ATTR which manifests later in life. The segment demonstrates specific therapeutic challenges related to comorbidities and drug tolerance. Adult patients with hereditary forms require earlier interventions, creating distinct treatment paradigms and follow-up requirements across different age cohorts. |
| By Therapeutic Approach |
|
Gene Silencing Therapies represent the most innovative and rapidly evolving segment with several RNA-targeted therapies showing promising clinical outcomes. This approach directly addresses disease pathology rather than symptoms, creating significant interest among clinicians and patients. The segment benefitsfrom strong pipeline activity and novel mechanism of action beyond conventional treatment paradigms. |
| By Disease Manifestation |
|
Cardiac Amyloidosis has emerged as the clinically dominant manifestation with increasing recognition among heart failure patients. The segment benefits from improved diagnostic techniques and dedicated cardiac biomarkers. Neuropathic forms continue to present significant diagnostic challenges, while mixed phenotypes require complex, multispecialty management approaches and combination therapies. |
Innovative Biopharma Companies Driving ATTR Treatment Advancements
Pfizer dominates the ATTR amyloidosis market with its flagship drug Vyndaqel (tafamidis), which has shown significant efficacy in treating both hereditary and wild-type ATTR-CM. The company continues to invest heavily in R&D for next-generation therapies, maintaining a strong competitive edge. Alnylam Pharmaceuticals follows closely with its RNAi therapeutic Onpattro (patisiran), specifically targeting polyneuropathy in hATTR patients, representing a breakthrough in gene silencing technology.
Several biotech firms are making notable strides in niche segments of the ATTR market. Ionis Pharmaceuticals, through its subsidiary Akcea Therapeutics, markets Tegsedi (inotersen) for polyneuropathy treatment. Emerging players like Corino Therapeutics and Proclara Bioscience are developing novel approaches targeting TTR protein misfolding, while Arcturus Therapeutics explores mRNA-based solutions. The competitive landscape features increasing collaboration between pharmaceutical giants and specialized biotech firms to address different ATTR subtypes.
List of Key Transthyretin Amyloidosis (ATTR) Companies ProfiledCorino Therapeutics
Proclara Bioscience
Eidos Therapeutics
Intellia Therapeutics
SOM Biotech
NeuroPhage Pharmaceuticals
FoldRx Pharmaceuticals
BridgeBio Pharma
Alexion Pharmaceuticals
The global Transthyretin Amyloidosis (ATTR) market is experiencing significant growth, projected to expand at a CAGR of X% from 2024 to 2031. This growth is primarily fueled by increasing disease prevalence, particularly hereditary ATTR cases in the 7MM (US, EU5, and Japan). The United States currently accounts for approximately 60% of global cases, with over 50,000 diagnosed patients. Improved diagnostic techniques and aging populations are contributing to higher detection rates of both hereditary and wild-type ATTR amyloidosis.
Other TrendsShift Toward Targeted Therapies
The market is witnessing accelerated development of novel therapeutics, with RNA interference drugs and TTR stabilizers gaining traction. Key players like Alnylam Pharmaceuticals and Ionis Pharmaceuticals have launched breakthrough treatments that modify disease progression rather than just managing symptoms. The therapy pipeline currently includes over 15 investigational drugs in Phase II/III trials, indicating robust research activity in this space.
Regional Market DynamicsNorth America dominates with over 70% market share due to established healthcare infrastructure and high treatment adoption rates. Europe follows closely, with Germany and France showing particularly strong growth. Emerging markets in Asia-Pacific are projected to grow at an above-average CAGR, driven by improving diagnosis rates and healthcare access. The Middle East & Africa region, while smaller, is seeing increased investment in rare disease management programs.
Specialized Treatment Centers Expansion
There's growing emphasis on establishing specialized amyloidosis centers, particularly for ATTR management. Over 200 dedicated centers now exist globally, with 40% established in the past five years. This concentration of expertise is improving patient outcomes and standardizing care protocols across regions.
Diagnostic AdvancementsTechnological improvements in cardiac imaging and genetic testing are enabling earlier detection, expanding the addressable patient population. Non-invasive diagnostic methods now account for over 65% of new ATTR diagnoses, compared to just 30% five years ago. This trend is significantly reducing the diagnostic odyssey for patients, enabling earlier therapeutic intervention.
Regional Analysis: Transthyretin Amyloidosis (ATTR) MarketEurope
Europe shows uneven ATTR management, with Germany, France, and Nordic countries establishing national referral networks. EU approval of tafamidis preceded U.S. authorization, but reimbursement hurdles persist in Southern Europe. The UK's NHS faces budget constraints limiting rapid therapy adoption, while Germany's sickness funds provide broader access. Portugal's endemic focus areas around Porto drive specialized clinics and registry development. EU cross-border collaboration through THAOS registry enhances phenotype understanding. Eastern Europe lags in diagnostics, with many cases misdiagnosed as HFpEF.
Asia-Pacific
Japan leads Asia-Pacific through early local approvals of tafamidis and aggressive screening for wild-type ATTR in elderly populations. China shows rapidly growing awareness but faces diagnostic bottlenecks outside tier-1 cities. Korea's single-payer system enables centralized treatment protocols, while India struggles with genetic testing affordability. Australia's PBS listings make it a regional access leader. Southeast Asia sees rising wild-type ATTR detection with aging populations, but therapy costs remain prohibitive for most patients.
Latin America
Brazil dominates regional management through So Paulo's reference centers tracking Portuguese-descended populations. Argentina and Mexico show increasing specialist awareness but lack structured care pathways. Chile's concentrated health system enables focused provider education, while Andean countries face severe diagnostic delays. Economic volatility impacts sustainable therapy access, with most patients relying on judicial appeals for treatment funding.
Middle East & Africa
Israel maintains advanced capabilities through centralized amyloidosis centers in Tel Aviv. Gulf states import cutting-edge therapies but lack local epidemiological data. South Africa's private sector outperforms public hospitals in ATTR management. North Africa reports increasing case identification in Tunisia and Morocco, while Sub-Saharan Africa remains vastly underdiagnosed with sporadic reporting from referral centers in Nigeria and Kenya.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device manufacturers
Healthcare providers and hospital systems
Contract research organizations
Investors and policy makers
-> Global Transthyretin Amyloidosis (ATTR) market was valued at USD 3.2 billion in 2024 and is expected to reach USD 6.8 billion by 2031.
Which key companies operate in Global Transthyretin Amyloidosis (ATTR) Market?
-> Key players include Pfizer, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Corino Therapeutics, and Proclara Bioscience.
-> Key growth drivers include increasing disease awareness, improved diagnostics, and novel therapeutics development.
-> North America currently dominates the market, accounting for over 45% of global revenue.
-> Emerging trends include gene-silencing therapies, RNA interference drugs, and new treatment options for both hATTR and wtATTR.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates